Skip to main content
headshots of award winners with text CASP super stewards 2022

June 13, 2022

Alby, Kwan, Mangun, Miller, and Phillips Recognized for Exemplary Antimicrobial Stewardship Contributions

The Carolina Antimicrobial Stewardship Program (CASP) honored five collaborators with Super Steward Awards. Kevin Alby, PhD, Mildred Kwan, MD, PhD, Jesica Mangum, PharmD, Melissa Miller, PhD, and Michael Phillips, MD were among the award recipients. CASP created the awards in 2022 to recognize colleagues’ efforts to champion stewardship in their settings. “The extent of CASP’s …

bio pic of Zachary Willis

February 2, 2022

Updated Guidance on Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents

via the Journal of Pediatric Infectious Diseases Society Background Starting in November 2020, the US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) for multiple novel virus-neutralizing monoclonal antibody therapies, including bamlanivimab monotherapy (now revoked), bamlanivimab and etesivimab, casirivimab and imdevimab (REGEN-COV), and sotrovimab, for treatment or postexposure prophylaxis of Coronavirus disease …

January 3, 2022

Rapid Diagnostic Tests to Improve Antibiotic Stewardship for Pediatric Acute Respiratory Illnesses in Uganda

Globally, respiratory illness is one of the most common reasons that children seek care. It is often treated inappropriately with antibiotics, which can drive the development of antibiotic resistance. In resource-rich settings, testing for specific pathogens or measurement of clinical biomarkers, such as procalcitonin and C-reactive protein, is often employed to help determine which children …

graph of EAT free days

December 20, 2021

Early De-escalation of Empiric Antimicrobial Therapy in Acute Leukemia Patients with Febrile Neutropenia

CASP’s Bill Wilson, PharmD, Clinical Pharmacy Specialist, Infectious Diseases & Antimicrobial Stewardship in the UNC Children’s Hospital, was among the authors on a new article published today in Journal of Oncology Pharmacy Practice. Recent trials have shown early de-escalation of empiric antimicrobial therapy (EAT) in febrile neutropenia has led to less adverse effects with no …